Les résultats et les conclusions des travaux menés par l’écosystème Experts Recherche Lymphome sont publiés dans des journaux médicaux de premier plan.
Lysa
2025_Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort
Cancer Epidemiol 2025;96:102812
En savoir plus
Lysa
2025_Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
Nat Cancer 2025;:
En savoir plus
Lysa
2025_High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial
Hemasphere 2025;9:e70105
En savoir plus
Lysa
2025_Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA
EClinicalMedicine 2025;82:103157
En savoir plus
Lysa
2025_Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines
Eur J Cancer 2025;220:115369
En savoir plus
Lysa
2025_Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials
Eur J Nucl Med Mol Imaging 2025;:
En savoir plus
Lysa
2025_A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis
Br J Haematol 2025;:
En savoir plus
Lysa
2025_Interim PET after 4 Cycles Predicts Outcome in Histomolecularly Confirmed Primary Mediastinal B-Cell Lymphoma
Blood Adv 2025;:bloodadvances.2024015577
En savoir plus
Lysa
2025_PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction
Computerized Medical Imaging and Graphics 2025;120:102481
En savoir plus
Lysa
2025_Personalized baseline and residual TMTV influence treatment response and outcomes in relapsed/refractory lymphomas: results from the GATA study
Eur J Nucl Med Mol Imaging 2025;:
En savoir plus
Lysa
2025_Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry
Hemasphere 2025;9:e70091
En savoir plus
Lysa
2025_Outcome of high-grade B-cell lymphoma compared to other large B-cell lymphoma after CAR-T rescue. A DESCAR-T LYSA study
Blood Adv 2025;:bloodadvances.2024014732
En savoir plus
Lysa
2025_T cell malignancies after CAR T cell therapy in the DESCAR-T registry
Nat Med 2025;:
En savoir plus
Lysa
2024_Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
Blood 2024;144:2503-2516
En savoir plus
Lysa
2024_Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
European Journal of Cancer 2024;213:115073
En savoir plus
Lysa
2024_Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Blood Cancer J 2024;14:197
En savoir plus
Lysa
2024_Precautions to Consider in the Analysis of Prognostic and Predictive Indices
2024;65:1672-1678
En savoir plus
Lysa
2024_Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study
Hematol Oncol 2024;42:e3314
En savoir plus
Lysa
2024_Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials
J Cancer Surviv 2024;:
En savoir plus
Lysa
2024_A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry
Adv Ther 2024;:
En savoir plus
Lysa
2024_Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5′ RACE
Blood Adv 2024;:bloodadvances.2024013723
En savoir plus
Lysa
2024_Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)
J Clin Oncol 2024;:JCO2400554
En savoir plus
Lysa
2024_MYC Rearrangement Prediction from LYSA Whole Slide Images in Large B-cell Lymphoma: A Multi-centric Validation of Self-supervised Deep Learning Models
Mod Pathol 2024;:100610
En savoir plus
Lysa
2024_International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
J Nucl Med 2024;65:1343-1348
En savoir plus